This is therefore a comparing of the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation in scPharmaceuticals Inc. (NASDAQ:SCPH) and Matinas BioPharma Holdings Inc. (NYSEAMERICAN:MTNB). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
scPharmaceuticals Inc.	N/A	0.00	31.22M	-1.68	0.00
Matinas BioPharma Holdings Inc.	N/A	873.66	14.87M	-0.16	0.00

Table 1 highlights scPharmaceuticals Inc. and Matinas BioPharma Holdings Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows scPharmaceuticals Inc. and Matinas BioPharma Holdings Inc.’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
scPharmaceuticals Inc.	0.00%	-33.2%	-28.4%
Matinas BioPharma Holdings Inc.	0.00%	0%	-104.5%

Liquidity

scPharmaceuticals Inc.’s Current Ratio and Quick Ratio are 13 and 13 respectively. The Current Ratio and Quick Ratio of its competitor Matinas BioPharma Holdings Inc. are 2.9 and 2.9 respectively. scPharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Matinas BioPharma Holdings Inc.

Institutional & Insider Ownership

Institutional investors owned 77.2% of scPharmaceuticals Inc. shares and 11.7% of Matinas BioPharma Holdings Inc. shares. scPharmaceuticals Inc.’s share owned by insiders are 17.25%. Competitively, insiders own roughly 0.7% of Matinas BioPharma Holdings Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
scPharmaceuticals Inc.	0.62%	-16.15%	-30.28%	-36.13%	-79.41%	-13.03%
Matinas BioPharma Holdings Inc.	18.35%	17.27%	54.07%	200%	27.72%	116.81%

For the past year scPharmaceuticals Inc. had bearish trend while Matinas BioPharma Holdings Inc. had bullish trend.

Summary

On 5 of the 7 factors Matinas BioPharma Holdings Inc. beats scPharmaceuticals Inc.

scPharmaceuticals Inc., biopharmaceutical company, engages in the development and commercialization of transformative pharmaceutical products. The company's under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid-based drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an orally-administered cochleate formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of aminoglycoside antibiotic agent amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring strategic partnership options for MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.